Clene Announces Positive Results of Phase 2 ALS Trials for CNM-Au8
Clene (NASDAQ: CLNN) announces positive Phase 2 ALS trial results for CNM-Au8, showing significant improvement in biomarkers. CEO expresses optimism about the potential of CNM-Au8 as a new treatment for ALS.
This news matters as it highlights the potential of CNM-Au8 as a new treatment for ALS, providing hope for patients and their families. The positive results of the clinical trials and the company's pursuit of an accelerated approval pathway could lead to a significant impact on the treatment of ALS and the lives of those affected by the disease.
